Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

7.98
+0.31004.04%
Post-market: 7.90-0.0800-1.00%19:54 EDT
Volume:765.31K
Turnover:6.06M
Market Cap:213.07M
PE:-4.77
High:8.05
Open:7.73
Low:7.70
Close:7.67
52wk High:11.00
52wk Low:3.71
Shares:26.70M
Float Shares:24.28M
Volume Ratio:1.74
T/O Rate:3.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6715
EPS(LYR):-5.6466
ROE:-141.14%
ROA:-45.66%
PB:7.06
PE(LYR):-1.41

Loading ...

Unicycive Therapeutics posts corporate presentation on kidney disease treatments

Reuters
·
8 hours ago

B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target

MT Newswires Live
·
May 01

Unicycive Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

Unicycive director Gaurav Aggarwal resigns from board

Reuters
·
Apr 06

Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark

Dow Jones
·
Apr 06

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

TIPRANKS
·
Apr 06

Unicycive Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 02

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

TIPRANKS
·
Apr 02

Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date

Reuters
·
Apr 02

Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate

Benzinga
·
Mar 30

Unicycive Therapeutics presentation highlights OLC NDA review for dialysis hyperphosphatemia treatment

Reuters
·
Mar 30

Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Unicycive FY25 net loss narrows 28% to USD 27 million

Reuters
·
Mar 30

Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns

TIPRANKS
·
Mar 18

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Pipeline and OLC Hyperphosphatemia Program

Reuters
·
Mar 06

Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Mar 02

Unicycive Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Feb 20

Unicycive Therapeutics initiated with a Buy at WestPark Capital

TIPRANKS
·
Feb 19

Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements

Reuters
·
Feb 17

Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC

Reuters
·
Feb 07